相关实验视频
Updated: Jan 13, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
子牛奶衍生生物活性作为多功能抗高血糖,氧化应激和糖化剂:一项综合实验和计算研究
Akshaya Simha Naganarasimha1, Shashank M Patil1, Ramith Ramu1
1Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru 570015, Karnataka, India.
子牛奶酸具有治疗2型糖尿病 (T2DM) 的潜力. 一个,ADVFNPR,有效地抑制了关键的糖尿病标,并清除了有害基因,这表明它可以作为T2DM并发症的食品衍生辅助剂.
科学领域:
- 食品科学 食品科学 食品科学
- 生物化学 生化学
- 营养保健品 营养保健品
背景情况:
- 2型糖尿病 (T2DM) 标志着高血糖和先进的糖化最终产品 (AGE) 积累.
- 食品衍生的被探索为它们在T2DM中的潜在的多功能调节作用.
- 在T2DM管理中子奶的潜力在很大程度上未经研究.
研究的目的:
- 探索子牛奶的抗高血糖和抗糖化潜力.
- 识别和描述子奶中的特定酸具有T2DM治疗特性.
主要方法:
- 从子奶中获取的蛋白质被酶性地化成.
- 使用纳米-ESI-Orbitrap-LC-MS/MS识别了类蛋白,并在基中选针对糖尿病标 (α-葡萄糖酶,α-氨酶,阿尔多减少酶) 和AGE受体 (RAGE) 的活性.
- 选择的被合成并在体外评估酶抑制,激素清除和血液溶解活性.
主要成果:
- 确定了114种,ADVFNPR显示出明显抑制α-葡萄糖酶,α-氨酶和阿尔多减少酶.
- 通过清除甲基和各种自由基 (DPPH,ABTS,超氧化物),ADVFNPR显示出强大的抗氧化活性.
- 酸ADVFNPR表现出具有竞争力的抑制动力学和低血解活性.
结论:
- 子牛奶含有多功能,具有显著的抗高血糖,抗糖化和抗氧化特性.
- 酸ADVFNPR显示出作为一种潜在的食物衍生的辅助物来管理T2DM及其相关并发症的承诺.
- 这些子奶衍生的进一步开发可能为T2DM管理提供新的策略.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
12:32High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...